|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Van Cutsem E, Sagaert X, Topal B,
Haustermans K and Prenen H: Gastric cancer. Lancet. 388:2654–2664.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Orditura M, Galizia G, Sforza V,
Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J,
Savastano B, Mabilia A, et al: Treatment of gastric cancer. World J
Gastroenterol. 20:1635–1649. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Karimi P, Islami F, Anandasabapathy S,
Freedman ND and Kamangar F: Gastric cancer: Descriptive
epidemiology, risk factors, screening, and prevention. Cancer
Epidemiol Biomarkers Prev. 23:700–713. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Song Z, Wu Y, Yang J, Yang D and Fang X:
Progress in the treatment of advanced gastric cancer. Tumour Biol.
39:10104283177146262017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu WK, Cho CH, Lee CW, Fan D, Wu K, Yu J
and Sung J: Dysregulation of cellular signaling in gastric cancer.
Cancer Lett. 295:144–153. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fresno Vara JA, Casado E, de Castro J,
Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hennessy BT, Smith DL, Ram PT, Lu Y and
Mills GB: Exploiting the PI3K/AKT pathway for cancer drug
discovery. Nat Rev Drug Discov. 4:988–1004. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang J, Xu J, Dong Y and Huang B:
Down-regulation of HIF-1α inhibits the proliferation, migration,
and invasion of gastric cancer by inhibiting PI3K/AKT pathway and
VEGF expression. Biosci Rep. 38:BSR201807412018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gupta AK, Cerniglia GJ, Mick R, Ahmed MS,
Bakanauskas VJ, Muschel RJ and McKenna WG: Radiation sensitization
of human cancer cells in vivo by inhibiting the activity of PI3K
using LY294002. Int J Radiat Oncol Biol Phys. 56:846–853. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ao R, Guan L, Wang Y and Wang JN:
Silencing of COL1A2, COL6A3, and THBS2 inhibits gastric cancer cell
proliferation, migration, and invasion while promoting apoptosis
through the PI3k-Akt signaling pathway. J Cell Biochem.
119:4420–4434. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kumari S, Puneet, Prasad SB, Yadav SS,
Kumar M, Khanna A, Dixit VK, Nath G, Singh S and Narayan G: Cyclin
D1 and cyclin E2 are differentially expressed in gastric cancer.
Med Oncol. 33:402016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Riquelme I, Tapia O, Espinoza JA, Leal P,
Buchegger K, Sandoval A, Bizama C, Araya JC, Peek RM and Roa JC:
The Gene expression status of the PI3K/AKT/mTOR pathway in gastric
cancer tissues and cell lines. Pathol Oncol Res. 22:797–805. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou R, Xu L, Ye M, Liao M, Du H and Chen
H: Formononetin inhibits migration and invasion of MDA-MB-231 and
4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through
PI3K/AKT signaling pathways. Horm Metab Res. 46:753–760. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou H, Wu J, Wang T, Zhang X and Liu D:
CXCL10/CXCR3 axis promotes the invasion of gastric cancer via
PI3K/AKT pathway-dependent MMPs production. Biomed Pharmacother.
82:479–488. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chang F, Lee JT, Navolanic PM, Steelman
LS, Shelton JG, Blalock WL, Franklin RA and McCubrey JA:
Involvement of PI3K/Akt pathway in cell cycle progression,
apoptosis, and neoplastic transformation: A target for cancer
chemotherapy. Leukemia. 17:590–603. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu C, Ho PC, Wong FC, Sethi G, Wang LZ
and Goh BC: Garcinol: Current status of its anti-oxidative,
anti-inflammatory and anti-cancer effects. Cancer Lett. 362:8–14.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Saadat N and Gupta SV: Potential role of
garcinol as an anticancer agent. J Oncol. 2012:6472062012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Oike T, Ogiwara H, Torikai K, Nakano T,
Yokota J and Kohno T: Garcinol, a histone acetyltransferase
inhibitor, radiosensitizes cancer cells by inhibiting
non-homologous end joining. Int J Radiat Oncol Biol Phys.
84:815–821. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yamaguchi F, Saito M, Ariga T, Yoshimura Y
and Nakazawa H: Free radical scavenging activity and antiulcer
activity of garcinol from garcinia indica fruit rind. J Agric Food
Chem. 48:2320–2325. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liao CH, Sang S, Ho CT and Lin JK:
Garcinol modulates tyrosine phosphorylation of FAK and subsequently
induces apoptosis through down-regulation of Src, ERK, and Akt
survival signaling in human colon cancer cells. J Cell Biochem.
96:155–169. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Y, Tsai ML, Chiou LY, Ho CT and Pan
MH: Antitumor activity of garcinol in human prostate cancer cells
and xenograft mice. J Agric Food Chem. 63:9047–9052. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Aggarwal S and Das SN: Garcinol inhibits
tumour cell proliferation, angiogenesis, cell cycle progression and
induces apoptosis via NF-κB inhibition in oral cancer. Tumor
Biology. 37:7175–7184. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jo H, Mondal S, Tan D, Nagata E, Takizawa
S, Sharma AK, Hou QM, Shanmugasundaram K, Prasad A, Tung JK, et al:
Small molecule-induced cytosolic activation of protein kinase Akt
rescues ischemia-elicited neuronal death. Proc Natl Acad Sci USA.
109:105812012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhou XY, Cao J, Han CM, Li SW, Zhang C, Du
YD, Zhou QQ, Zhang XY and Chen X: The C8 side chain is one of the
key functional group of Garcinol for its anti-cancer effects.
Bioorg Chem. 71:74–80. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ahmad A, Sarkar SH, Aboukameel A, Ali S,
Biersack B, Seibt S, Li YW, Bao B, Kong D, Banerjee S, et al:
Anticancer action of garcinol in vitro and in vivo is in part
mediated through inhibition of STAT-3 signaling. Carcinogenesis.
33:2450–2456. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Parasramka MA and Gupta SV: Garcinol
inhibits cell proliferation and promotes apoptosis in pancreatic
adenocarcinoma cells. Nutr Cancer. 63:456–465. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ahmad A, Wang Z, Ali R, Maitah MY, Kong
DJ, Banerjee S, Padhye S and Sarkar FH: Apoptosis-inducing effect
of garcinol is mediated by NF-kappaB signaling in breast cancer
cells. J Cell Biochem. 109:1134–1141. 2010.PubMed/NCBI
|
|
30
|
Sethi G, Chatterjee S, Rajendran P, Li F,
Shanmugam MK, Wong KF, Kumar AP, Senapati P, Behera AK, Hui KM, et
al: Inhibition of STAT3 dimerization and acetylation by garcinol
suppresses the growth of human hepatocellular carcinoma in vitro
and in vivo. Molecular Cancer. 13:662014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hammarton TC, Engstler M and Mottram JC:
The Trypanosoma brucei Cyclin, CYC2, is required for cell
cycle progression through G1 phase and for maintenance of procyclic
form cell morphology. J Biol Chem. 279:24757–24764. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Arand J and Sage J: G1 cyclins protect
pluripotency. Nat Cell Biol. 19:149–150. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gao Z, Zhu M, Wu Y, Gao P, Qin Z and Wang
H: Interferon-lambda1 induces G1 phase cell cycle arrest and
apoptosis in gastric carcinoma cells in vitro. Oncol Rep.
32:199–204. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lang SA, Gaumann A, Koehl GE, Seidel U,
Bataille F, Klein D, Ellis LM, Bolder U, Hofstaedter F, Schlitt HJ,
et al: Mammalian target of rapamycin is activated in human gastric
cancer and serves as a target for therapy in an experimental model.
Int J Cancer. 120:1803–1810. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Feng W, Brown RE, Trung CD, Li W, Wang LW,
Khoury T, Alrawi S, Yao J, Xia K and Tan D: Morphoproteomic profile
of mTOR, Ras/Raf Kinase/ERK, and NF-κB pathways in human gastric
adenocarcinoma. Ann Clin Lab Sci. 38:195–209. 2008.PubMed/NCBI
|
|
36
|
Advani SH: Targeting mTOR pathway: A new
concept in cancer therapy. Indian J Med Paediatr Oncol. 31:132–136.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Resnitzky D and Reed SI: Different roles
for cyclins D1 and E in regulation of the G1-to-S transition. Mol
Cell Biol. 15:34631995. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Adams JM and Cory S: The Bcl-2 apoptotic
switch in cancer development and therapy. Oncogene. 26:1324–1337.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhou SY, Baltimore D, Cantley LC, Kaplan
DR and Franke TF: Interleukin 3-dependent survival by the Akt
protein kinase. Proc Natl Acad Sci USA. 94:11345–11350. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Geng W and Zhang HY: Research on the
mechanism of HP mediated PI3K/AKT/GSK3β pathways in gastric cancer.
Eur Rev Med Pharmacol Sci. 21 (Suppl 3):S33–S37. 2017.
|
|
43
|
Nagy TA, Frey MR, Yan F, Israel DA, Polk
DB and Peek RM Jr: Helicobacter pylori regulates cellular migration
and apoptosis by activation of phosphatidylinositol 3-kinase
signaling. J Infect Dis. 199:641–651. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Morita M, Gravel SP, Hulea L, Larsson O,
Pollak M, St-Pierre J and Topisirovic I: mTOR coordinates protein
synthesis, mitochondrial activity and proliferation. Cell Cycle.
14:473–480. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tapia O, Riquelme I, Leal P, Sandoval A,
Aedo S, Weber H, Letelier P, Bellolio E, Villaseca M, Garcia P and
Roa JC: The PI3K/AKT/mTOR pathway is activated in gastric cancer
with potential prognostic and predictive significance. Virchows
Archiv. 465:25–33. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mayer IA and Arteaga CL: The PI3K/AKT
pathway as a target for cancer treatment. Annu Rev Med. 67:11–28.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Cheng TC, Din ZH, Su JH, Wu YJ and Liu CI:
Sinulariolide suppresses cell migration and invasion by inhibiting
matrix metalloproteinase-2/-9 and urokinase through the
PI3K/AKT/mTOR signaling pathway in human bladder cancer cells. Mar
Drugs. 15:E2382017. View Article : Google Scholar : PubMed/NCBI
|
